These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
383 related articles for article (PubMed ID: 27039970)
1. Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension. Di Marco V; Calvaruso V; Ferraro D; Bavetta MG; Cabibbo G; Conte E; Cammà C; Grimaudo S; Pipitone RM; Simone F; Peralta S; Arini A; Craxì A Gastroenterology; 2016 Jul; 151(1):130-139.e2. PubMed ID: 27039970 [TBL] [Abstract][Full Text] [Related]
2. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response. Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617 [TBL] [Abstract][Full Text] [Related]
3. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Mira JA; Rivero-Juárez A; López-Cortés LF; Girón-González JA; Téllez F; de los Santos-Gil I; Macías J; Merino D; Márquez M; Ríos-Villegas MJ; Gea I; Merchante N; Rivero A; Torres-Cornejo A; Pineda JA; Clin Infect Dis; 2013 Jun; 56(11):1646-53. PubMed ID: 23429381 [TBL] [Abstract][Full Text] [Related]
4. Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response. Fernández-Rodríguez CM; Alonso S; Martinez SM; Forns X; Sanchez-Tapias JM; Rincón D; Rodriguez-Caravaca G; Bárcena R; Serra MA; Romero-Gómez M; Fernandez I; Garcia-Samaniego J; Fuente J; Solá R; Moreno-Otero R; Planas R; Am J Gastroenterol; 2010 Oct; 105(10):2164-72; quiz 2173. PubMed ID: 20700116 [TBL] [Abstract][Full Text] [Related]
5. Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model. Petta S; Di Marco V; Bruno S; Enea M; Calvaruso V; Boccaccio V; Rossi S; Craxì A; Cammà C Liver Int; 2016 Dec; 36(12):1765-1773. PubMed ID: 27164508 [TBL] [Abstract][Full Text] [Related]
7. The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy. D'Ambrosio R; Aghemo A; Rumi MG; Primignani M; Dell'Era A; Lampertico P; Donato MF; De Nicola S; Prati GM; de Franchis R; Colombo M Antivir Ther; 2011; 16(5):677-84. PubMed ID: 21817189 [TBL] [Abstract][Full Text] [Related]
8. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Bruno S; Crosignani A; Facciotto C; Rossi S; Roffi L; Redaelli A; de Franchis R; Almasio PL; Maisonneuve P Hepatology; 2010 Jun; 51(6):2069-76. PubMed ID: 20196120 [TBL] [Abstract][Full Text] [Related]
9. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V; Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836 [TBL] [Abstract][Full Text] [Related]
10. Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy. Thabut D; Bureau C; Layese R; Bourcier V; Hammouche M; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Goria O; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle-Bladou C; Dao T; Pilette C; Silvain C; Christidis C; Capron D; Bernard-Chabert B; Hillaire S; Di Martino V; Sutton A; Audureau E; Roudot-Thoraval F; Nahon P; Gastroenterology; 2019 Mar; 156(4):997-1009.e5. PubMed ID: 30768988 [TBL] [Abstract][Full Text] [Related]
11. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. Cardoso AC; Moucari R; Figueiredo-Mendes C; Ripault MP; Giuily N; Castelnau C; Boyer N; Asselah T; Martinot-Peignoux M; Maylin S; Carvalho-Filho RJ; Valla D; Bedossa P; Marcellin P J Hepatol; 2010 May; 52(5):652-7. PubMed ID: 20346533 [TBL] [Abstract][Full Text] [Related]
12. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin. Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084 [TBL] [Abstract][Full Text] [Related]
13. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. Afdhal NH; Dusheiko GM; Giannini EG; Chen PJ; Han KH; Mohsin A; Rodriguez-Torres M; Rugina S; Bakulin I; Lawitz E; Shiffman ML; Tayyab GU; Poordad F; Kamel YM; Brainsky A; Geib J; Vasey SY; Patwardhan R; Campbell FM; Theodore D Gastroenterology; 2014 Feb; 146(2):442-52.e1. PubMed ID: 24126097 [TBL] [Abstract][Full Text] [Related]
14. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients. Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511 [TBL] [Abstract][Full Text] [Related]
15. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. Bruno S; Zuin M; Crosignani A; Rossi S; Zadra F; Roffi L; Borzio M; Redaelli A; Chiesa A; Silini EM; Almasio PL; Maisonneuve P Am J Gastroenterol; 2009 May; 104(5):1147-58. PubMed ID: 19352340 [TBL] [Abstract][Full Text] [Related]
16. Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy. Lens S; Rincón D; García-Retortillo M; Albillos A; Calleja JL; Bañares R; Abraldes JG; Bosch J; Sanchez-Tapias JM; Forns X; García-Pagán JC Clin Gastroenterol Hepatol; 2015 Oct; 13(10):1846-1853.e1. PubMed ID: 25912838 [TBL] [Abstract][Full Text] [Related]
17. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. Nahon P; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Roudot-Thoraval F; Audureau E; Gastroenterology; 2018 Nov; 155(5):1436-1450.e6. PubMed ID: 30031138 [TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of patients with chronic hepatitis C treated with α-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response. Cordero-Ruiz P; Carmona-Soria I; Rodríguez-Téllez M; Caunedo-Alvarez A; Quezada-Pacheco RH; Flores-Cucho A; Romero-Gómez M; Vilches-Arenas Á Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):792-799. PubMed ID: 28445251 [TBL] [Abstract][Full Text] [Related]
19. Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis. Mira JA; García-Rey S; Rivero A; de los Santos-Gil I; López-Cortés LF; Girón-González JA; Téllez F; Márquez M; Merino D; Ríos-Villegas MJ; Macías J; Rivero-Juárez A; Pineda JA Clin Infect Dis; 2012 Dec; 55(12):1719-26. PubMed ID: 22955435 [TBL] [Abstract][Full Text] [Related]
20. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. Braks RE; Ganne-Carrie N; Fontaine H; Paries J; Grando-Lemaire V; Beaugrand M; Pol S; Trinchet JC World J Gastroenterol; 2007 Nov; 13(42):5648-53. PubMed ID: 17948941 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]